[The cancer immunotherapy controlled by the number of PHA-blastogenic cells]

Old BRMs have been conventionally evaluated by comparative studies between the cancer patients treated with or without BRMs. This comparison should be done under the assumption that effectiveness of BRMs is dose-dependent. However BRMs can not be effective without enhancing cellular immunity of the patients. We have demonstrated that PHA blastogenic reaction was not necessarily augmented in vitro in a dose-related manner by MRMs. Nor did the dose-dependent immuno-enhancement always occur by clinical use of BMRs, if the blastogenic ratio was converted to the number of blastogenic cells per mm3 of peripheral blood to monitor the patient's cellular immunity more precisely. If BRMs should be reviewed in terms of the immuno-enhancing activity by the number of PHA blastogenic cells, the clinical needs of BRMs must be increased. It is sure that the patient's survival could be improved if immunotherapy should be done with varying doses or schedule individually by using the adequate immuno-parameters such as PHA blastogenic reaction.